Impressive Moves in the Worlds of Neurotech & Biotech

Spring has sprung and so have results from biotech and neurotech companies. If you're new to our newsletter - welcome to your hub for monthly news on the latest investment and R&D news in Brain Health, Mental Health, and HealthTech!

A New Era for Anxiety Treatment: FDA Breakthrough Therapy Designation for LSD-Based Drug

The FDA has granted MindMed 's LSD-based drug, MM120, breakthrough therapy designation for treating anxiety. MindMed's clinical trials have showcased a 48% remission rate in anxiety patients from a single dose, signaling a shift from traditional, often addictive treatments to innovative, non-addictive alternatives. Read More.

A Waiting Game: EU's Deliberates on Eisai-Biogen's Alzheimer's Drug Leqembi

The European Union's medicines regulator has postponed its decision on Eisai Co., Ltd. and Biogen 's Alzheimer's drug, lecanemab, known as Leqembi in the United States. Leqembi, which has already gained traditional approval in the United States, Japan, China and other countries, represents a hopeful advancement in Alzheimer's treatment by targeting amyloid beta clumps in the brain. Read More.

Battle of the BCIs: Neuralink vs Synchron

Less known to mainstream headlines, Synchron , a leading innovator in the brain-computer interface sector, has taken a significant step by acquiring an equity stake in a manufacturing firm. This strategic acquisition aims to bolster Synchron's manufacturing capabilities, positioning it as a formidable contender against the likes of Neuralink . This acquisition not only accelerates Synchron's path to commercializing brain-computer interfaces but also signifies the burgeoning interest and investment in neurotechnology. Read More.

More on Brain Health:

• Neurotech International Ltd brings in massive returns: Neurotech International (ASX:NTI) celebrates a monumental five-year journey with a staggering 479% increase in share price, showcasing the immense potential of long-term investment in the healthcare sector. Read More.
• Anima closes $12 million Series A round: Anima aims to revolutionize healthcare clinics with a platform that combines the best of Slack, Salesforce, and Figma, ensuring seamless operations and enhanced patient care. Read More.
• The CareVoice closes $10 million Series B round: This round stands out in signaling strong investor confidence in its unique approach to embedded health solutions. Read More.
• Deep Brain Stimulation Rewires the Battle Against OCD: The 英国剑桥大学 's recent study highlights the effectiveness of deep brain stimulation. offering new hope for treatment-resistant cases through targeted brain interventions. Read More.

PortCo Milestones:

• SOM Biotech closes €5.5 million funding round: This round is to support the completion of a Phase IIb study on it's promising Huntington's disease treatment. Read More.
• Gedea Biotech AB secures EIC €2.5M Grant for Novel Antibiotics: This grant will advance their pioneering work on next-generation antibiotics, marking a crucial step in combating antibiotic resistance. Read More.

Bonus Invite:

• Psychedelics x Mental Health: Join us and The New Health Club for a brilliant panel with experts in the field to get insights and a glimpse into one of the most exciting industries and markets emerging in the coming years. Bring your questions and your old narratives about psychedelics, so we can crush them! See you April 17th at the Home Grown Club . Get Tickets.

Follow for more on Brain Health & HealthTech

We hope you enjoyed the read! Join our newsletter list to receive your monthly updates on Brain Health & HealthTech. Let's tackle the Brain Health mission together. ??